Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

0 avis

Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

Archive ouverte

Edité par CCSD ; Elsevier -

International audience. Recent studies showed that patients with glioma can safely participate in early phase clinical trials; however, clinical benefits in this population were limited. We aimed to evaluate the benefit of molecular profiling to guide enrolment in early phase trials for patients with recurrent glioma.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

Archive ouverte | Besle, Sylvain | CCSD

International audience. Abstract Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In th...

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience

Archive ouverte | Besle, Sylvain | CCSD

International audience. PURPOSE:Enrolment process influences the likelihood of patients' inclusion in early clinical trials (ECT) through social, medical and organisational factors.PATIENTS AND METHODS:All patients ...

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Archive ouverte | Baldini, Capucine | CCSD

International audience. Background: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in pa...

Chargement des enrichissements...